Analyst Travis Steed of Bank of America Securities maintained a Buy rating on Medtronic (MDT – Research Report), retaining the price ...

Medtronic PLC closed $2.15 below its 52-week high ($91.49), which the company reached on September 4th.

Medtronic (NYSE: MDT) has named Jorie Soskin as its new VP and GM of its TAVR and Congenital Heart businesses.

Medtronic, a global developer and manufacturer of medical devices for chronic diseases, is now a $111 billion (by market cap) ...

Shares of Medtronic PLC MDT advanced 1.52% to $89.47 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.70% to 5,713.64 ...

Medtronic plc (NYSE:MDT ... Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, ...

Medtronic faced challenges, including poor focus, lack of innovation, and COVID-19 impact, leading to share price stagnation since 2018. Despite recent improvements in performance, Medtronic ...

In April, Medtronic obtained FDA approval for another new product, Inceptiv, a spinal cord stimulator for treating chronic pain. The device can automatically adjust the therapy — a unique feature — to ...

The recent boost is partly due to Medtronic's newest insulin pump, the MiniMed 780G ... There will continue to be a dire need for products that help simplify the lives of these patients.